- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT01936844
Interleukin (IL)-1 Blockade in Acute Heart Failure (Anakinra ADHF)
Interleukin-1 Blockade in Acute Decompensated Heart Failure
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og plasseringer
Studiesteder
-
-
Virginia
-
Richmond, Virginia, Forente stater, 23298
- Virginia Commonwealth University
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
All 5 criteria need to be met for enrollment of the patient in the study
Primary diagnosis of acute decompensated heart failure within the last 24 hours as evidenced by both of the following:
- dyspnea or respiratory distress or tachypnea at rest or with minimal exertion
- evidence of elevated cardiac filling pressure or pulmonary congestion (at least one of the conditions must be met);
i. pulmonary congestion/edema at physical exam OR chest x-ray; ii. plasma Brain Natriuretic Peptide (BNP) levels ≥200 pg/mL; iii.invasive measurement of left ventricular end-diastolic pressure >18 mmHg or of pulmonary artery occluding pressure (wedge) >16 mmHg.
- Left ventricular systolic dysfunction (LVEF<40%) during index hospitalization or prior 12 months.
- Age ≥18 years old
- Willing and able to provide written informed consent.
- Screening plasma C-reactive protein levels >5 mg/L.
Exclusion Criteria Subjects will not be eligible if they meet any of the following 15 exclusion criteria.
- The primary diagnosis for admission is NOT decompensated heart failure, including diagnosis of acute coronary syndromes, hypertensive urgency/emergency, tachy- or brady-arrhythmias.
- Concomitant clinically significant comorbidities that would interfere with the execution or interpretation of the study including but not limited to acute coronary syndromes, uncontrolled hypertension or orthostatic hypotension, tachy- or brady-arrhythmias, acute or chronic pulmonary disease or neuromuscular disorders affecting respiration.
- Recent (previous 3 months) or planned cardiac resynchronization therapy (CRT), coronary artery revascularization procedures, or heart valve surgeries.
- Previous or planned implantation of left ventricular assist devices or heart-transplant.
- Chronic use of intravenous inotropes.
- Recent (<14 days) use of immunosuppressive or anti-inflammatory drugs (not including Non-Steroidal Anti-Inflammatory Drugs [NSAIDs]).
- Chronic inflammatory disorder (including but not limited to rheumatoid arthritis, systemic lupus erythematosus).
- Active infection (of any type);
- Chronic/recurrent infectious disease (including Hepatitis B virus [HBV], Hepatitis C virus [HCV], and HIV/AIDS).
- Prior (within the past 10 years) or current malignancy.
- Any comorbidity limiting survival or ability to complete the study.
- End stage kidney disease requiring renal replacement therapy.
- Neutropenia (<2,000/mm3) or Thrombocytopenia (<50,000/mm3).
- Pregnancy.
- Angina, arrhythmias, or electrocardiograph (ECG) changes that limit maximum exertion during cardiopulmonary exercise testing obtained during the baseline testing.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Firemannsrom
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Anakinra (short)
Anakinra 100 mg twice daily for the first 3 days followed by 100 mg daily for days 4-14
|
Anakinra 100 mg daily twice daily for days 1, 2, and 3
Anakinra 100 mg daily for days 4-14
|
Placebo komparator: Placebo
Placebo injections twice daily for the first 3 days then once daily for days 4-14.
|
Placebo twice daily for days 1, 2, and 3
Placebo daily for days 4-14
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
C Reactive Protein
Tidsramme: 3 days
|
The proportional area-under-the-curve for plasma C reactive protein (CRP) levels measured during the first 3 days of admission.
The proportion (y-axis) is calculated at each time-point with respect to the baseline CRP.
The resultant y-axis is a unitless proportion.
The x-axis is listed as "days"
|
3 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Left Ventricular Ejection Fraction
Tidsramme: 14 days
|
Change in left ventricular ejection fraction (LVEF) between admission and 14 day follow up.
This value is expressed as absolute change in measured LVEF.
For example, if baseline LVEF = 20% and 14 day LVEF = 25%, this would be reported as an absolute change of 5%.
|
14 days
|
Brachial Artery Vasoreactivity
Tidsramme: 14 days
|
Change in flow mediated vasodilatation (FMD) of the brachial artery.
Brachial artery FMD is calculated as the percentage increase in brachial artery diameter with hyperemia (an increase in the quantity of blood flow to a body part) induced relative to the resting brachial artery diameter.
Percentage of brachial artery diameter is measured as FMD diameter/basal diameter.
The change is FMD is reported as the % change in FMD from baseline to 14 days.
|
14 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Benjamin W Van Tassell, PharmD, Virginia Commonwealth University
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- VCU HM15347
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Hjertefeil
-
Region SkanePåmelding etter invitasjonHjertesvikt New York Heart Association (NYHA) klasse II | Hjertesvikt New York Heart Association (NYHA) klasse IIISverige
-
Medical University of BialystokInstitute of Cardiology, Warsaw, Poland; Medical University of Lodz; Poznan... og andre samarbeidspartnereHar ikke rekruttert ennåHjertesvikt, systolisk | Hjertesvikt med redusert utkastningsfraksjon | Hjertesvikt New York Heart Association Klasse IV | Hjertesvikt New York Heart Association klasse IIIPolen
-
Luigi Sacco University HospitalIRCCS Azienda Ospedaliero-Universitaria di Bologna; University of Padova; Università degli Studi di Ferrara og andre samarbeidspartnereRekrutteringAtrieflimmer | Block Complete HeartItalia, Belgia, Sveits
-
University of WashingtonAmerican Heart AssociationFullførtHjertesvikt, Kongestiv | Mitokondriell endring | Hjertesvikt New York Heart Association Klasse IVForente stater
-
Novartis PharmaceuticalsFullførtPasienter som har fullført den 12-måneders behandlingsperioden i kjernestudien (de Novo Heart-mottakere) som var interessert i å bli behandlet med EC-MPS
-
University Hospital, GasthuisbergUkjentTransient Left Ventricular Ballooning SyndromeBelgia
-
NYU Langone HealthRekrutteringTako-tsubo kardiomyopati | Takotsubo kardiomyopati | Broken Heart SyndromeForente stater
-
French Cardiology SocietyFullført
Kliniske studier på Anakinra (high dose)
-
Tongji HospitalRekrutteringRemimazolam | Våken endotrakeal intubasjonKina
-
Riphah International UniversityFullførtHamstring StramhetPakistan
-
Ohio State UniversityAvsluttetDiabetes mellitus, type 2 | Blodsukker, høy | Pasientutskrivning | Blodglukose, lavForente stater
-
University Hospital, Clermont-FerrandFullført
-
Henrik EndemanFranciscus Gasthuis; Maasstad HospitalRekrutteringRespirasjonssvikt | Etter ekstubering Akutt respirasjonssvikt som krever reintuberingNederland
-
The University of Texas at DallasUniversity of Texas Southwestern Medical CenterRekrutteringMinneforstyrrelser | Vanskelighet for å finne ordForente stater
-
University of RochesterHar ikke rekruttert ennåPediatrisk astma
-
National Taiwan University HospitalUkjent
-
Centre Hospitalier Universitaire de BesanconCentre Hospitalier Universitaire Dijon; Poitiers University Hospital; University... og andre samarbeidspartnereRekruttering
-
Turkish Society of Anesthesiology and ReanimationHar ikke rekruttert ennåApné | Hypoksi